Literature DB >> 30865584

Malaria blood safety policy in five non-endemic countries: a retrospective comparison through the lens of the ABO risk-based decision-making framework.

Sheila F O'Brien1, Sheila Ward2, Pierre Gallian3, Cécile Fabra4, Josiane Pillonel5, Alan D Kitchen6, Katy Davison7, Clive R Seed8, Gilles Delage9, Whitney R Steele10, David A Leiby11.   

Abstract

BACKGROUND: In non-endemic countries, malaria risk is addressed by selectively testing or deferring at-risk donors. These policy decisions were made using a variety of decision-making frameworks prior to the development of the Alliance of Blood Operators Risk Based Decision-Making Framework. It is unclear whether the range of items assessed in the decision-making process would be increased if the Framework were used. We compared assessments considered in France, England and Australia for decisions to implement selective testing, plus donor selection criteria (Canada and the USA included) with those recommended by the Framework.
MATERIALS AND METHODS: Elements of the Framework were identified: the intervention, safety threat, availability threat, donor impact, financial implications, risk communication, stakeholder and regulatory aspects. Decisions about selective testing and donor selection criteria were analysed separately. Assessments were compared against elements of the Framework and the level of concern for considerations rated.
RESULTS: Sufficiency of the blood supply (plus safety in France) were the drivers for selective testing; main trade-offs were high operational impact and cost. In three donor criteria examples, transfusion-transmitted malaria cases prompted the change. Social concerns were high in France and Australia, political/regulatory concerns influenced decisions in France, Australia and Canada, while sufficiency was a consideration in Canada and the USA. Decision trade-offs involved moderate operational impact. DISCUSSION: The assessments considered in each country were generally consistent with the assessments recommended by the Framework. When data supported quantified risk assessment, safety and operational feasibility had the greatest weight. When risk was not well defined, contextual factors such as social and political concern had greater weight.

Entities:  

Mesh:

Year:  2019        PMID: 30865584      PMCID: PMC6476743          DOI: 10.2450/2019.0222-18

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  22 in total

1.  Transfusion-transmitted malaria in Canada.

Authors:  R Slinger; A Giulivi; M Bodie-Collins; F Hindieh; R S John; G Sher; M Goldman; M Ricketts; K C Kain
Journal:  CMAJ       Date:  2001-02-06       Impact factor: 8.262

2.  Deconstructing the risk for malaria in United States donors deferred for travel to Mexico.

Authors:  Bryan Spencer; Steven Kleinman; Brian Custer; Ritchard Cable; Susan L Wilkinson; Whitney Steele; Patrick M High; David Wright
Journal:  Transfusion       Date:  2011-05-12       Impact factor: 3.157

3.  How safe is safe enough, who decides and how? From a zero-risk paradigm to risk-based decision making.

Authors:  Jay E Menitove; Judie Leach Bennett; Peter Tomasulo; Louis M Katz
Journal:  Transfusion       Date:  2014-03       Impact factor: 3.157

4.  [Transfusional serology of malaria by an indirect immunofluorescence test using the Plasmodium berghei antigen].

Authors:  M Gentilini; D Richard-Lenoble; J Reviron; M Farragi
Journal:  Rev Fr Transfus Immunohematol       Date:  1976-06

Review 5.  Donor deferral policies for men who have sex with men: past, present and future.

Authors:  M Goldman; A W-Y Shih; S F O'Brien; D Devine
Journal:  Vox Sang       Date:  2017-12-13       Impact factor: 2.144

6.  Evaluation of a malarial antibody assay for use in the screening of blood and tissue products for clinical use.

Authors:  A D Kitchen; P H J Lowe; K Lalloo; P L Chiodini
Journal:  Vox Sang       Date:  2004-10       Impact factor: 2.144

7.  Detection of malarial DNA in blood donors--evidence of persistent infection.

Authors:  A D Kitchen; P L Chiodini; J Tossell
Journal:  Vox Sang       Date:  2014-03-21       Impact factor: 2.144

8.  Multicentric evaluation of the DiaMed enzyme-linked immunosorbent assay malaria antibody test for screening of blood donors for malaria.

Authors:  M-H Elghouzzi; A Senegas; T Steinmetz; P Guntz; V Barlet; A Assal; P Gallian; P Volle; C Chuteau; M Beolet; S Berrebi; D Filisetti; C Doderer; T Abdelrahman; E Candolfi
Journal:  Vox Sang       Date:  2007-11-16       Impact factor: 2.144

9.  [Post-tranfusional malaria in France].

Authors:  J Ranque
Journal:  Rev Fr Transfus Immunohematol       Date:  1976-06

10.  [Prevention of post-transfusional malaria by sero-detection of latent Plasmodium carriers among blood donors].

Authors:  P Ambroise-Thomas
Journal:  Rev Fr Transfus Immunohematol       Date:  1976-06
View more
  5 in total

1.  A WHO tool for risk-based decision making on blood safety interventions.

Authors:  Mart P Janssen; C Micha Nuebling; François-Xavier Lery; Yuyun S Maryuningsih; Jay S Epstein
Journal:  Transfusion       Date:  2020-12-25       Impact factor: 3.157

2.  The hidden Plasmodium malariae in blood donors: a risk coming from areas of low transmission of malaria.

Authors:  Mariana Aschar; José Eduardo Levi; Maria L R N Farinas; Sandra C Montebello; Alfredo Mendrone-Junior; Silvia Maria Di Santi
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2020-12-18       Impact factor: 1.846

Review 3.  Transfusion-Transmitted Malaria and Mitigation Strategies in Nonendemic Regions.

Authors:  Christoph Niederhauser; Susan A Galel
Journal:  Transfus Med Hemother       Date:  2022-07-15       Impact factor: 4.040

4.  Robust inactivation of Plasmodium falciparum in red blood cell concentrates using amustaline and glutathione pathogen reduction.

Authors:  Cissé Sow; Amélie Bouissou; Yvette A Girard; Gurvani B Singh; Lotfi Bounaadja; Jean-Marc Payrat; Delphine Haas; Hervé Isola; Marion C Lanteri; Peter Bringmann; Philippe Grellier
Journal:  Transfusion       Date:  2022-04-06       Impact factor: 3.337

5. 

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2022-04       Impact factor: 1.513

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.